We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Earlier Measurements Offer Quicker Treatment for Sepsis

By LabMedica International staff writers
Posted on 07 Jun 2018
Sepsis remains a significant cause of morbidity and mortality in the USA, leading to the implementation of the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1). More...
SEP-1 identifies patients with “severe sepsis” via clinical and laboratory criteria and mandates interventions, including lactate draws and antibiotics, within a specific time window.

Because of a known association between elevated lactate levels and increased mortality, sepsis guidelines mandate that lactate levels should be tested soon after the onset of sepsis. A new study found that a significant proportion of patients with suspected sepsis do not have their lactates measured within the recommended timeframe.

Medical scientists at the University of Chicago (Chicago, IL, USA) reviewed the records of close to 150,000 patients admitted to a single tertiary care academic hospital from November 2008 to January 2016. Information regarding each patient's characteristics, vital signs, laboratory measurements, and medical therapy was analyzed. There was a particular focus on lactate measurements and levels.

The team identified 5,762 admissions that met the three SEP-1 criteria for severe sepsis within a six-hour period. Of these, only 60% had an initial lactate drawn within the SEP-1 specified timeframe. The team reported that 14% had their levels measured between three and 24 hours after the time of first suspicion of sepsis ("delayed lactates"), and more than one quarter had no lactate measurements at all. Whether lactates were measured promptly varied with where the patient was being treated; 79% of patients treated in the emergency department had levels measured within the specified time period compared with 55% in the intensive care unit (ICU) but only 32% in hospital wards.

Patients with delayed lactate measurements demonstrated the highest in-hospital mortality at 29%, with increased time to antibiotic administration (median time, 3.9 hours versus 2.0 hours). Patients with initial lactates greater than 2.0 mmol/L demonstrated an increase in the odds of death with hourly delay in lactate measurement (odds ratio = 1.02). The authors concluded that delays in lactate measurement are associated with delayed antibiotics and increased mortality in patients with initial intermediate or elevated lactate levels. Systematic early lactate measurement for all patients with sepsis will lead to a significant increase in lactate draws that may prompt more rapid physician intervention for patients with abnormal initial values.

Matthew M. Churpek, MD, MPH, PhD, an Assistant Professor of Medicine and lead investigator of the study, said, “Systematic early lactate measurements in patients presenting with sepsis would result in a significant increase in the number of lactates measured on patients but may be of benefit in identifying patients with elevated initial lactates who are at risk for poorer outcomes. Patients with early lactate measurements received earlier interventions such as antibiotic administration, which is known to improve mortality in sepsis.” The study was published on May 24, 2018, in the journal CHEST.

Related Links:
University of Chicago


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.